Response to the Letter to the Editor Regarding “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Response to Letter]

Figures & data

Table 1 Indirect Comparison of Pneumonia Incidence Rates and Event Rates in the ETHOS and IMPACT Studies

Treatment	Incidence Rate (% of Patients)	Event Rate (per 1000 Patient-Years)
Budesonide (320 µg)/glycopyrrolate/formoterol fumarate^Citation13	4.6	53.3
Glycopyrrolate/formoterol fumarate^Citation13	2.9	37.3
Rate ratio	1.6	1.4
Fluticasone furoate/umeclidinium/vilanterol^Citation14	8	95.8
Umeclidinium/vilanterol^Citation14	5	61.2
Rate ratio	1.6	1.6

Note: The bolded values in the table are the rate ratios of the event rates in the ETHOS and IMPACT studies, respectively.

Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046

 PubMed Web of Science ®Google Scholar

Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901

 PubMed Web of Science ®Google Scholar